Base-editing corrects metabolic abnormalities in a humanized mouse model for glycogen storage disease type-Ia
Authors:
Open Access
- 10 November 2024
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-18
Abstract
Glycogen storage disease type-Ia patients, deficient in the G6PC1 gene encoding glucose-6-phosphatase-α, lack blood glucose control, resulting in life-threatening hypoglycemia. Here we show our humanized mouse model, huR83C, carrying the pathogenic G6PC1-R83C variant displays the phenotype of glycogen storage disease type-Ia and dies prematurely. We evaluate the efficacy of BEAM-301, a formulation of lipid nanoparticles containing a newly-engineered adenine base editor, to correct the G6PC1-R83C variant in huR83C mice and monitor phenotypic correction through one year. BEAM-301 can correct up to ~60% of the G6PC1-R83C variant in liver cells, restores blood glucose control, improves metabolic abnormalities of the disease, and confers long-term survival to the mice. Interestingly, just ~10% base correction is therapeutic. The durable pharmacological efficacy of base editing in huR83C mice supports the development of BEAM-301 as a potential therapeutic for homozygous and compound heterozygous glycogen storage disease type-Ia patients carrying the G6PC1-R83C variant.Keywords
All Related Versions
This publication has 53 references indexed in Scilit:
- CRISPR/Cas9‐based double‐strand oligonucleotide insertion strategy corrects metabolic abnormalities in murine glycogen storage disease type‐IaJournal of Inherited Metabolic Disease, 2023
- Biomarkers of liver diseasesMolecular Biology Reports, 2023
- The Delivery of ABE mRNA to the Adult Murine Liver by Lipid Nanoparticles (LNPs)2023
- Lipid-based nanoparticle technologies for liver targetingAdvanced Drug Delivery Reviews, 2020
- Tight metabolic control plus ACE inhibitor therapy improves GSD I nephropathyJournal of Inherited Metabolic Disease, 2017
- Type I glycogen storage diseases: disorders of the glucose‐6‐phosphatase/glucose‐6‐phosphate transporter complexesJournal of Inherited Metabolic Disease, 2014
- Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapyHepatology, 2012
- Mutations in the glucose-6-phosphatase-α (G6PC) gene that cause type Ia glycogen storage diseaseHuman Mutation, 2008
- A new microtechnique for the analysis of the human hepatic microsomal glucose-6-phosphatase systemClinica Chimica Acta, 1988
- The effect of handling techniques on serum alt activity in miceJournal of Applied Toxicology, 1985